|Articles|July 1, 2019
- Pharmaceutical Executive-07-01-2019
- Volume 39
- Issue 7
Pharmaceutical Executive, July 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Creating an ‘Unbossed’ Environment in the Workplaceover 6 years ago
Proposed Rebates Rule Raises Tough Questionsover 6 years ago
Drug Formulary Decisions: Fixing a Broken Systemover 6 years ago
The Feasibility of Patient Insights Before Launchover 6 years ago
Compliance Disruptorsover 6 years ago
Asia’s Complex Compliance Landscapeover 6 years ago
European Pricing Talks: A lot of Smoke—or is it Fire?over 6 years ago
FDA Maps Pathway to More Accessible Biosimilarsover 6 years ago
Top Trends, Takeaways from DIAover 6 years ago
Pharma & Biotech: Financial Pulse-Check, OutlookNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
